Jane Street’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $125M | Sell |
161,500
-354,700
| -69% | -$272M | 0.02% | 554 |
|
|
2025
Q4 | $398M | Buy |
516,200
+70,500
| +16% | +$47.9M | 0.06% | 213 |
|
|
2025
Q3 | $251M | Buy |
445,700
+367,700
| +471% | +$208M | 0.04% | 292 |
|
|
2025
Q2 | $41M | Buy |
78,000
+20,500
| +36% | +$11.4M | 0.01% | 896 |
|
|
2025
Q1 | $36.5M | Buy |
57,500
+17,600
| +44% | +$12.1M | 0.01% | 858 |
|
|
2024
Q4 | $28.4M | Sell |
39,900
-33,700
| -46% | -$28.3M | 0.01% | 1015 |
|
|
2024
Q3 | $77.4M | Buy |
73,600
+42,700
| +138% | +$47.5M | 0.02% | 490 |
|
|
2024
Q2 | $32.5M | Sell |
30,900
-15,200
| -33% | -$14.7M | 0.01% | 930 |
|
|
2024
Q1 | $44.4M | Sell |
46,100
-5,500
| -11% | -$5.23M | 0.01% | 696 |
|
|
2023
Q4 | $45.3M | Buy |
51,600
+9,200
| +22% | +$7.58M | 0.01% | 729 |
|
|
2023
Q3 | $34.9M | Sell |
42,400
-16,600
| -28% | -$13M | 0.01% | 733 |
|
|
2023
Q2 | $42.4M | Buy |
59,000
+11,500
| +24% | +$8.87M | 0.01% | 689 |
|
|
2023
Q1 | $39M | Sell |
47,500
-25,600
| -35% | -$19.3M | 0.02% | 623 |
|
|
2022
Q4 | $52.7M | Buy |
73,100
+1,700
| +2% | +$1.25M | 0.02% | 502 |
|
|
2022
Q3 | $49.2M | Sell |
71,400
-29,000
| -29% | -$18.3M | 0.02% | 526 |
|
|
2022
Q2 | $59.3M | Buy |
100,400
+26,400
| +36% | +$17.2M | 0.03% | 477 |
|
|
2022
Q1 | $51.7M | Sell |
74,000
-59,900
| -45% | -$37.9M | 0.02% | 671 |
|
|
2021
Q4 | $84.6M | Sell |
133,900
-6,400
| -5% | -$3.93M | 0.03% | 422 |
|
|
2021
Q3 | $84.9M | Buy |
140,300
+5,500
| +4% | +$3.41M | 0.03% | 395 |
|
|
2021
Q2 | $75.3M | Buy |
134,800
+46,900
| +53% | +$23.8M | 0.03% | 395 |
|
|
2021
Q1 | $41.6M | Sell |
87,900
-2,800
| -3% | -$1.36M | 0.02% | 556 |
|
|
2020
Q4 | $43.8M | Buy |
90,700
+32,100
| +55% | +$17.3M | 0.02% | 496 |
|
|
2020
Q3 | $32.8M | Sell |
58,600
-13,700
| -19% | -$8.31M | 0.02% | 541 |
|
|
2020
Q2 | $45.1M | Sell |
72,300
-67,200
| -48% | -$38.1M | 0.03% | 395 |
|
|
2020
Q1 | $68.1M | Buy |
139,500
+99,900
| +252% | +$41.2M | 0.07% | 190 |
|
|
2019
Q4 | $14.9M | Buy |
39,600
+11,000
| +38% | +$3.7M | 0.02% | 484 |
|
|
2019
Q3 | $7.93M | Buy |
28,600
+3,400
| +13% | +$1.01M | 0.01% | 712 |
|
|
2019
Q2 | $7.89M | Buy |
25,200
+500
| +2% | +$166K | 0.01% | 757 |
|
|
2019
Q1 | $10.1M | Buy |
24,700
+500
| +2% | +$206K | 0.02% | 676 |
|
|
2018
Q4 | $9.04M | Buy |
24,200
+8,300
| +52% | +$3.04M | 0.02% | 635 |
|
|
2018
Q3 | $6.42M | Sell |
15,900
-23,200
| -59% | -$8.83M | 0.01% | 874 |
|
|
2018
Q2 | $13.5M | Buy |
39,100
+9,600
| +33% | +$3M | 0.03% | 465 |
|
|
2018
Q1 | $10.2M | Sell |
29,500
-307,700
| -91% | -$107M | 0.03% | 542 |
|
|
2017
Q4 | $127M | Buy |
337,200
+317,200
| +1,586% | +$128M | 0.36% | 36 |
|
|
2017
Q3 | $8.94M | Sell |
20,000
-36,000
| -64% | -$17.1M | 0.03% | 566 |
|
|
2017
Q2 | $27.5M | Buy |
56,000
+21,800
| +64% | +$9.54M | 0.1% | 189 |
|
|
2017
Q1 | $13.3M | Sell |
34,200
-77,400
| -69% | -$28.7M | 0.06% | 296 |
|
|
2016
Q4 | $41M | Buy |
111,600
+94,500
| +553% | +$35.9M | 0.18% | 94 |
|
|
2016
Q3 | $6.88M | Sell |
17,100
-214,900
| -93% | -$86.2M | 0.03% | 442 |
|
|
2016
Q2 | $81M | Buy |
232,000
+218,700
| +1,644% | +$84.2M | 0.4% | 42 |
|
|
2016
Q1 | $4.79M | Sell |
13,300
-5,300
| -28% | -$2.18M | 0.03% | 591 |
|
|
2015
Q4 | $10.1M | Buy |
18,600
+14,100
| +313% | +$7.64M | 0.06% | 264 |
|
|
2015
Q3 | $2.09M | Sell |
4,500
-11,700
| -72% | -$6.28M | 0.01% | 942 |
|
|
2015
Q2 | $8.26M | Buy |
16,200
+13,900
| +604% | +$6.78M | 0.05% | 302 |
|
|
2015
Q1 | $1.04M | Buy |
+2,300
| New | +$975K | 0.01% | 1346 |
|
Other funds holding REGN
VCM
N
Jane Street's REGN Position: Q1 2026 in Review
Jane Street reduced its Regeneron Pharmaceuticals (REGN) stake by 57% in Q1 2026, selling an estimated $5.55M and leaving 5,374 shares worth $4.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3783.
Jane Street first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $150M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Jane Street held 5,374 shares of Regeneron Pharmaceuticals worth $4.15M as of Q1 2026.
- Jane Street sold 7,247 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $5.55M.
- Regeneron Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3783 holding.
- Jane Street first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Jane Street's Regeneron Pharmaceuticals position peaked at $150M in Q2 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.